GlassScriptPhysician profile
Pasquale Brancazio
NPI 1891856951
$18,082.10
in general payments reported to CMS, 2019-2025
41 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,426 · 2021: $16.34 · 2022: $19.00 · 2023: $182 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $300 · Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $300.00 |
| Food and Beverage | $266.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,054.66 | 2019-2020 | |
| Celgene Corporation | $5,568.19 | 2019 | |
| Biogen, INC. | $922.95 | 2019-2025 | Tysabri |
| Teva Pharmaceuticals USA, INC. | $787.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $711.49 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $371.75 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $330.04 | 2019-2020 | |
| Ucb, INC. | $202.89 | 2019-2020 | |
| Lilly USA, LLC | $194.15 | 2019-2025 | Kisunla |
| Emd Serono, INC. | $187.66 | 2019 | |
| Amgen INC. | $153.27 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $152.77 | 2019-2020 | |
| Eisai INC. | $139.67 | 2019-2025 | |
| Greenwich Biosciences, INC. | $110.96 | 2019 | |
| Vertical Pharmaceuticals, LLC | $102.76 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $96.59 | 2019-2020 | |
| Genentech USA, INC. | $92.67 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $81.72 | 2019-2020 | |
| Tanabe Pharma America, INC. | $73.01 | 2019 | |
| Acorda Therapeutics, INC | $68.96 | 2019 | |
| Acadia Pharmaceuticals INC | $63.87 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $63.12 | 2019 | |
| Neurocrine Biosciences, INC. | $50.66 | 2019 | |
| Csl Behring | $47.42 | 2019 | |
| Mallinckrodt Enterprises LLC | $46.80 | 2019 | |
| Lundbeck LLC | $43.14 | 2019-2020 | |
| Grifols USA, LLC | $35.42 | 2019 | |
| Allergan, INC. | $35.13 | 2020-2021 | |
| Bausch Health US, LLC | $34.89 | 2019 | |
| Abbvie INC. | $31.81 | 2023 | Botox |
| Merz North America, INC. | $27.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.86 | 2020 | |
| Akcea Therapeutics, INC. | $25.32 | 2019 | |
| Livanova USA, INC. | $24.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.01 | 2020 | |
| Jazz Pharmaceuticals INC. | $23.34 | 2019 | |
| Boston Scientific Corporation | $19.00 | 2022 | |
| Aquestive Therapeutics, INC. | $18.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.60 | 2020 | |
| Strongbridge US INC. | $12.85 | 2019 | |
| Pfizer INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pasquale Brancazio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.